

TITLE: DIFFERENTIAL BIOMARKERS OF ASTHMA

FIELD OF INTEREST

Biotechnology (Asthma, Biomarkers, Personalised medicine)

CLINICAL NEED

Despite clinical heterogeneity of asthma, allergic mechanisms have been implicated in 50-80% of asthmatic patients and in approximately 50% of severe asthma. At the moment there is no robust evidence to recommend a classification of asthma in general based on phenotypes that may be useful when applying a specific personalised patient's treatment.

DESCRIPTION OF THE INVENTION

The invention comprises a panel of 8 proteins as potential differential biomarkers of several clinical phenotypes of asthma: Nonallergic Asthma (NA), Allergic Asthma (AA) and Allergy without Asthma (A), as well as, differential biomarkers of severity in asthma: Severe NA vs Moderate-mild NA and Severe AA vs Moderate-mild AA.

TECHNOLOGY KEYWORDS

Titanium, Protein, Genetic, Biomarkers, Asthmatic phenotypes, Asthma severity, NA, AA, A

IPR STATUS

Patent application number: P201730947// PCT/ES2018/070515.

Applicants: IIS-FJD.

TYPE AND ROLE OF PARTNER

Looking for technological partners for going through clinical trials as well as commercial partners interested in licensing.

Contact details:

Innovation Unit

e-mail: irene.ruano@fjd.es

Phone number: 0034-915504800 Ext.3455